Endocrinology, Vol 126, 1569-1575, Copyright © 1990 by Endocrine Society

ARTICLES

Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells

TL McCarthy, M Centrella and E Canalis
Department of Medicine (Endocrine Section), Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105.

Supraphysiological levels of cortisol inhibit bone cell replication and matrix synthesis, but its mechanism of action is unknown and could be secondary to an inhibition of local growth factor synthesis. These inhibitory effects of cortisol are the converse of the observed anabolic influences of the endogenously produced insulin-like growth factor-I (IGF-I); therefore, cortisol was examined for its effect on the production of IGF-I in osteoblast (Ob)- and fibroblast/preosteoblast-enriched cell cultures prepared from fetal rat parietal bone. Synthesis of IGF-I was monitored by Northern blot analysis to determine steady state IGF-I mRNA levels and by an IGF-I- specific RIA to quantitate polypeptide levels in acidified and fractionated culture medium. Cortisol at 100 nM decreased IGF-I transcript levels by 60% or more in Ob cultures within 6 h of treatment, and the concentration of immunoreactive IGF-I by 50% after 24 h; these effects were observed in the absence of a change in cellular DNA content. In Ob cultures, PTH at 10 nM increased IGF-I transcripts at 6 h and polypeptide levels at 24 h by 2.5- and 4.1-fold, respectively, and cortisol opposed this effect. The inhibitory effect of cortisol was not specific for the Ob cell population, since at 100 nM it also decreased IGF-I transcript and immunoreactive IGF-I levels in fibroblast/preosteoblast cultures and opposed the stimulation of IGF- I synthesis after treatment with 100 ng/ml GH. In conclusion, high levels of cortisol decrease skeletal IGF-I synthesis by reducing IGF-I transcript levels, and this effect probably contributes to the inhibitory influence of cortisol on bone formation.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				T. Shimoaka, S. Kamekura, H. Chikuda, K. Hoshi, U.-i. Chung, T. Akune, Z. Maruyama, T. Komori, M. Matsumoto, W. Ogawa, et al. Impairment of Bone Healing by Insulin Receptor Substrate-1 Deficiency J. Biol. Chem., April 9, 2004; 279(15): 15314 - 15322. [Abstract] [Full Text] [PDF]

				T. L. McCarthy, C. Ji, Y. Chen, K. Kim, and M. Centrella Time- and Dose-Related Interactions between Glucocorticoid and Cyclic Adenosine 3',5'-Monophosphate on CCAAT/Enhancer-Binding Protein-Dependent Insulin-Like Growth Factor I Expression by Osteoblasts Endocrinology, January 1, 2000; 141(1): 127 - 137. [Abstract] [Full Text] [PDF]

				Y. Umayahara, J. Billiard, C. Ji, M. Centrella, T. L. McCarthy, and P. Rotwein CCAAT/Enhancer-binding Protein delta  Is a Critical Regulator of Insulin-like Growth Factor-I Gene Transcription in Osteoblasts J. Biol. Chem., April 9, 1999; 274(15): 10609 - 10617. [Abstract] [Full Text] [PDF]

				C. Jux, K. Leiber, U. Hugel, W. Blum, C. Ohlsson, G. Klaus, and O. Mehls Dexamethasone Impairs Growth Hormone (GH)-Stimulated Growth by Suppression of Local Insulin-Like Growth Factor (IGF)-I Production and Expression of GH- and IGF-I-Receptor in Cultured Rat Chondrocytes Endocrinology, July 1, 1998; 139(7): 3296 - 3305. [Abstract] [Full Text] [PDF]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				Y. Umayahara, C. Ji, M. Centrella, P. Rotwein, and T. L. McCarthy CCAAT/Enhancer-binding Protein delta  Activates Insulin-like Growth Factor-I Gene Transcription in Osteoblasts. IDENTIFICATION OF A NOVEL CYCLIC AMP SIGNALING PATHWAY IN BONE J. Biol. Chem., December 12, 1997; 272(50): 31793 - 31800. [Abstract] [Full Text] [PDF]

				A. P.J. King, M.-J. Tseng, C. D. Logsdon, N. Billestrup, and C. Carter-Su Distinct Cytoplasmic Domains of the Growth Hormone Receptor Are Required for Glucocorticoid- and Phorbol Ester-induced Decreases in Growth Hormone (GH) Binding. THESE DOMAINS ARE DIFFERENT FROM THAT REPORTED FOR GH-INDUCED RECEPTOR INTERNALIZATION J. Biol. Chem., July 26, 1996; 271(30): 18088 - 18094. [Abstract] [Full Text] [PDF]

				B. Gabbitas, J. M. Pash, A. M. Delany, and E. Canalis Cortisol Inhibits the Synthesis of Insulin-like Growth Factor-binding Protein-5 in Bone Cell Cultures by Transcriptional Mechanisms J. Biol. Chem., April 12, 1996; 271(15): 9033 - 9038. [Abstract] [Full Text] [PDF]

				E. Smith, R. A. Redman, C. R. Logg, G. A. Coetzee, N. Kasahara, and B. Frenkel Glucocorticoids Inhibit Developmental Stage-specific Osteoblast Cell Cycle. DISSOCIATION OF CYCLIN A-CYCLIN-DEPENDENT KINASE 2 FROM E2F4-p130 COMPLEXES J. Biol. Chem., June 23, 2000; 275(26): 19992 - 20001. [Abstract] [Full Text] [PDF]